Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02213926 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT02213926 · ClinicalTrials.gov record · last posted 2026-08-04

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Name: An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma — clinical trial record (NCT02213926)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorAcerta Pharma BV

Started2015-03-02

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).

Amendment record 26 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 26 times since 2014-08-11; most recent amendment 2026-05-04. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2016-02-05

Status change Recruiting→Active, Not Recruitingv3

2014-12-20

Status change Not Yet Recruiting→Recruitingv1

Trial Details

NCT Number	NCT02213926
Lead Sponsor	Acerta Pharma BV
Conditions	Mantle Cell Lymphoma (MCL)
Enrollment	124 participants
Start Date	2015-03-02
Primary Completion	2020-12-04 (estimated)
Study Completion	2026-09-06 (estimated)
Updated on ClinicalTrials.gov	2026-08-04